Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Full text not currently available from Enlighten.


Purpose: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. Experimental Design: We analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis. Results: Five SNPs were significantly associated (P ≤ 1.0 × 10−5) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10−6). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤6 × 10−3). Conclusions: We have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Glasspool, Dr Rosalind and Paul, Mr James and Carty, Mrs Karen and Mcneish, Professor Iain
Authors: Johnatty, S. E., Tyrer, J. P., Kar, S., Beesley, J., Lu, Y., Gao, B., Fasching, P. A., Hein, A., Ekici, A. B., Beckmann, M. W., Lambrechts, D., Van Nieuwenhuysen, E., Vergote, I., Lambrechts, S., Rossing, M. A., Doherty, J. A., Chang-Claude, J., Modugno, F., Ness, R. B., Moysich, K. B., Levine, D. A., Kiemeney, L. A., Massuger, L. F. A. G., Gronwald, J., Lubi ski, J., Jakubowska, A., Cybulski, C., Brinton, L., Lissowska, J., Wentzensen, N., Song, H., Rhenius, V., Campbell, I., Eccles, D., Sieh, W., Whittemore, A. S., McGuire, V., Rothstein, J. H., Sutphen, R., Anton-Culver, H., Ziogas, A., Gayther, S. A., Gentry-Maharaj, A., Menon, U., Ramus, S. J., Pearce, C. L., Pike, M. C., Stram, D. O., Wu, A. H., Kupryjanczyk, J., Dansonka-Mieszkowska, A., Rzepecka, I. K., Spiewankiewicz, B., Goodman, M. T., Wilkens, L. R., Carney, M. E., Thompson, P. J., Heitz, F., du Bois, A., Schwaab, I., Harter, P., Pisterer, J., Hillemanns, P., Karlan, B. Y., Walsh, C., Lester, J., Orsulic, S., Winham, S. J., Earp, M., Larson, M. C., Fogarty, Z. C., Hogdall, E., Jensen, A., Kjaer, S. K., Fridley, B. L., Cunningham, J. M., Vierkant, R. A., Schildkraut, J. M., Iversen, E. S., Terry, K. L., Cramer, D. W., Bandera, E. V., Orlow, I., Pejovic, T., Bean, Y., Hogdall, C., Lundvall, L., McNeish, I., Paul, J., Carty, K., Siddiqui, N., Glasspool, R., Sellers, T., Kennedy, C., Chiew, Y.-E., Berchuck, A., MacGregor, S., Pharoah, P. D. P., Goode, E. L., deFazio, A., Webb, P. M., and Chenevix-Trench, G.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Clinical Cancer Research
Publisher:American Association for Cancer Research
ISSN (Online):1557-3265

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
415281Pharmacodynamics and drug resistanceRobert BrownCancer Research UK (CAN-RES-UK)C536/A6689RI CANCER SCIENCES
690421Glasgow Molecular Pathology (GMP) NodeKarin OienMedical Research Council (MRC)MR/N005813/1ICS - EXPERIMENTAL THERAPEUTICS